Table 4.

The incidence rate of IPD and NPP in the studies (rate per 100,000)

Author/Country	Age group	IPDa	NPPb (hospitalization)	Comments
Smith et al. 24/US	65–80+	25.9–60.1	567c	30% of all-cause CAP is pneumococcal
Weycker et al. 25/US	65–75	18	491	-
Smith et al. 26/US	60–69	58.52	868c	30% of all-cause CAP is pneumococcal
Smith et al. 27/US	60–69	25.9	567c	30% of all-cause CAP is pneumococcal
Cho et al. 28/US	≥65	6.8–550.6d	160–10330e	-
Boccalini et al. 29/Italy	65–74	9.5	42.2f	39.8% of all-cause CAP is pneumococcal
Liguori et al. 30/Italy	50–79	Expressed as total number/s	Expressed as total number/s	40% of all-cause CAP is pneumococcal
Rozenbaum et al. 32/Netherlands	65–69	47.4g	89	35% of all-cause CAP is pneumococcal
Rozenbaum et al. 31/England	≥65	43.5 (high risk group)	1210 (includes outpatient)	42% of all-cause CAP is pneumococcal
Pradas et al. 33/Spain	>50	29.7	318.7	50% of all-cause CAP is pneumococcal

^aIPD: Invasive pneumococcal disease.

^bNPP: Non-bactaeremic pneumococcal pneumonia.

^cIn all studies by Smith et al. the age group for NPP hospitalization was ≥65.

^dPCV13 serotype IPD rate 6.8–80.1 and PPV23 serotype IPD rate 43.8–550.6 dependent on immunosuppression condition.

^eNPP rate 160–10330 dependent on immunosuppression condition.

^fCalculated based on rate of non-invasive CAP, 31.8% of CAP hospitalized, and 39% of all cause CAP being pneumococcal.

^gCalculated based on addition of rates of different IPD cases.